Advertisement
UK markets open in 7 hours 55 minutes

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • HANG SENG

    17,763.03
    +16.12 (+0.09%)
     

  • CRUDE OIL

    79.06
    +0.06 (+0.08%)
     

  • GOLD FUTURES

    2,331.60
    +20.60 (+0.89%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • Bitcoin GBP

    46,070.37
    -2,209.88 (-4.58%)
     

  • CMC Crypto 200

    1,272.94
    -66.12 (-4.94%)
     

  • NASDAQ Composite

    15,605.48
    -52.34 (-0.33%)
     

  • UK FTSE All Share

    4,418.60
    -11.65 (-0.26%)
     
Money:

Family finances

Who is the breadwinner in your family and does it matter?

Amneal to Report First Quarter 2024 Results on May 3, 2024

Business Wire
·2-min read

BRIDGEWATER, N.J., April 10, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call.

ADVERTISEMENT

To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this link. The access code for the call is 172198.

A replay of the conference call will be posted shortly after the call and will be available for seven days.

About Amneal
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410515765/en/

Contacts

Investor Contact
Anthony DiMeo
Head of Investor Relations
anthony.dimeo@amneal.com